GlycoMimetics Inc. (GLYC), a biotechnology company, has a clinical trial catalyst to watch closely this quarter.
The company's lead drug candidate is Uproleselan, a first-in-class, E-selectin antagonist, which is a carbohydrate-binding transmembrane molecule expressed on the surface of blood vessels.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com